http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 12:31:07 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Board+Changes/NeOnc+Technologies+adds+strategy+executive+Nasim+Shomali+to+its+board/26816906.html <p>NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company focused on central nervous system cancer therapies, has appointed Nasim Shomali to its Board of Directors, effective July 1, 2026, according to a press release statement.</p> <p>Shomali brings more than a decade of experience in corporate strategy, financial planning, and organizational advisory roles. She most recently served as a strategy executive at Accenture, where she advised Fortune 100 and multinational companies across the life sciences, technology, and energy sectors. Her work included corporate strategy development, financial modeling, market sizing, and board-level advisory.</p> <p>Earlier in her career, Shomali held a private equity role http://www.streetinsider.com/Board+Changes/NeOnc+Technologies+adds+strategy+executive+Nasim+Shomali+to+its+board/26816906.html Mon, 27 Jul 2026 09:00:09 -0400 NTHI http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Appoints+Strategy+and+Finance+Executive+Nasim+Shomali+to+its+Board+of+Directors/26816871.html <p><strong>Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth</strong></p><p>CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026.</p> <p>"We are delighted to welcome Nasim to our Board at an important time for NeOnc," said Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "Nasim http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Appoints+Strategy+and+Finance+Executive+Nasim+Shomali+to+its+Board+of+Directors/26816871.html Mon, 27 Jul 2026 09:00:00 -0400 NTHI http://www.streetinsider.com/Globe+Newswire/NeOnc+Technologies+Appoints+Strategy+and+Finance+Executive+Nasim+Shomali+to+its+Board+of+Directors/26816871.html <p><strong>Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth</strong></p><p>CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026.</p> <p>"We are delighted to welcome Nasim to our Board at an important time for NeOnc," said Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "Nasim http://www.streetinsider.com/Globe+Newswire/NeOnc+Technologies+Appoints+Strategy+and+Finance+Executive+Nasim+Shomali+to+its+Board+of+Directors/26816871.html Mon, 27 Jul 2026 09:00:00 -0400 NTHI http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Press+Releases/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html <p>DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Xa2QaNJsKXCWms7dK9RIQp0YXrgRIehvDTYocr2TrZCoLG-6qqj5t4xIok8gh-cFuT05NW1ZqTaWJIffMLTMtIauwAprsKSwDsTAR1-SnmI=" rel="nofollow" target="_blank">247marketnews.com</a>) – Today’s announcements from <a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWXjysZxItVzId8MC2ODbTSNFXnXb1xdqnXDONMPwBlkIZ4aW1K4G7pnnKaZv9WY1paUHXMhFllAfJhZEkdK5uG1U8wfDDAWpWvdu7wrwVHHI" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=8dTR34khAnEsglablhA83cT8DwgrhBKqDDO0ht9yk0v4cVibq84QFq6DGV09WdgZN80_vOuOj7pBqt734WiQc1ucqW5pBR-FsdbJt8SoRm0Um2OaDw7ZtwgNcAfiJ6jR" rel="nofollow" target="_blank"><strong>Ernexa Therapeutics</strong></a> <strong>(NASDAQ: ERNA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=1OsK3FhwgyvF5fKET1PSN_EZ7217aBlFVEnm_Ho25XsxUtnCcLm0P-Gp_SNegRLnWOesL-w9N99wx7hqaeUWLOFW8RkQye94vtF-rSCLHXj1PaOHDVNHyV2xHRaMnAb8" rel="nofollow" target="_blank"><strong>VivoSim Labs</strong></a> <strong>(NASDAQ: VIVS)</strong> highlight three distinct pathways to potential value creation.</p> <p><strong>NeOnc Technologies</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=D0jGxULLZuP2W-LKOjbMWTvNtRVlYzrW3mjHwH2J2XBiyjfPHSRrt8nTEN7JdXsm3G3j_wHbdyG1kZ5BTKEwB_8bcW0BhOnhqs8xNj5_SwnU0HcGq8xxQSuKpOIQ6qrZ" rel="nofollow" target="_blank"><strong>NeOnc Technologies</strong></a> <strong>(NASDAQ: NTHI)</strong> announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, <strong>NEO212</strong>, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other http://www.streetinsider.com/Globe+Newswire/Three+Biotechs+Deliver+Catalysts+to+Watch/26772524.html Wed, 15 Jul 2026 10:42:42 -0400 ERNA ERNA ERNA LLY NTHI NTHI NTHI VIVS VIVS VIVS